Obesity III: Obesogen assays: Limitations, strengths, and new directions

Autor: Christopher D. Kassotis, Frederick S. vom Saal, Patrick J. Babin, Dominique Lagadic-Gossmann, Helene Le Mentec, Bruce Blumberg, Nicole Mohajer, Antoine Legrand, Vesna Munic Kos, Corinne Martin-Chouly, Normand Podechard, Sophie Langouët, Charbel Touma, Robert Barouki, Min Ji Kim, Karine Audouze, Mahua Choudhury, Nitya Shree, Amita Bansal, Sarah Howard, Jerrold J. Heindel
Přispěvatelé: Chard-Hutchinson, Xavier, Wayne State University [Detroit], University of Missouri [Columbia] (Mizzou), University of Missouri System, Université de Bordeaux (UB), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), University of California [Irvine] (UC Irvine), University of California (UC), Karolinska Institute, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Texas A&M University [College Station], Australian National University (ANU), Healthy Environment and Endocrine Disruptor Strategies (HEEDS)
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Biochemical Pharmacology
Biochemical Pharmacology, 2022, 199, pp.115014. ⟨10.1016/j.bcp.2022.115014⟩
Biochem Pharmacol
ISSN: 0006-2952
1873-2968
DOI: 10.1016/j.bcp.2022.115014⟩
Popis: International audience; There is increasing evidence of a role for environmental contaminants in disrupting metabolic health in both humans and animals. Despite a growing need for well-understood models for evaluating adipogenic and potential obesogenic contaminants, there has been a reliance on decades-old in vitro models that have not been appropriately managed by cell line providers. There has been a quick rise in available in vitro models in the last ten years, including commercial availability of human mesenchymal stem cell and preadipocyte models; these models require more comprehensive validation but demonstrate real promise in improved translation to human metabolic health. There is also progress in developing three-dimensional and co-culture techniques that allow for the interrogation of a more physiologically relevant state. While diverse rodent models exist for evaluating putative obesogenic and/or adipogenic chemicals in a physiologically relevant context, increasing capabilities have been identified for alternative model organisms such as Drosophila, C. elegans, zebrafish, and medaka in metabolic health testing. These models have several appreciable advantages, including most notably their size, rapid development, large brood sizes, and ease of high-resolution lipid accumulation imaging throughout the organisms. They are anticipated to expand the capabilities of metabolic health research, particularly when coupled with emerging obesogen evaluation techniques as described herein.
Databáze: OpenAIRE
Externí odkaz: